Stocks Abbott Laboratories

More

  • Cramer makes the call on viewers' favorite stocks.

  • Pharmaceutical stocks were winners today on the earnings front, and CNBC guests say they can be winners on the portfolio front as well.

  • webxtra_thumb.jpg

    Despite a slowing economy, drug stocks such as Abbott Labs and Genentech posted positive earnings reports. Is health care the best defensive play in this market?

  • graphic_fast_money.jpg

    After the volatile trading of the past several days, professional and amateur investors alike are throwing in the towel. But that might be a mistake.

  • graphic_final_trade.jpg

    Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • A first-of-its-kind study shows that putting hundreds of thousands of American heart patients on drugs instead of giving them a stent could save the country billions of dollars a year.

  • Boston Scientific Corp.

    Not too long ago, some had written off the potential for significant growth to resume in sales of the little wire mesh tubes that are painted with special drugs to help keep arteries from reclogging.

  • Cramer makes the call on viewers' favorite stocks.

  • The market cap of Dow component Johnson & Johnson is a whopping $200 billion. Abbott Labs is valued at less than half that. But think of ABT as kind of a mini-me JNJ because like Johnson & Johnson, ABT has cobbled together a similar three-siloed business of drugs, devices and consumer products.

  • A new study and an editorial in a major medical journal could reignite the debate over whether drugs or stents or a combination of both are better for the millions of Americans with heart trouble.

  • FED_RESERVE3.jpg

    Oil prices will be the trigger for stocks in the week ahead. The Fed meets Tuesday and as usual, traders will watch for nuances in the Fed's post-meeting statement.

  • Heart Stent

    Leerink Swann, which specializes in healthcare equities research, is out with a couple of noteworthy surveys--one on the collateral damage to Merck and Schering-Plough's Vytorin this week and the other on drug-coated stents from Abbott Labs, Boston Scientific, Johnson & Johnson and Medtronic.

  • webxtra_thumb.jpg

    In Wednesday’s Web Extra Pete Najarian reveals why he thinks the solar trade is starting to turn. Also “if you want to get into drugs” Guy Adami has your play.

  • abbott_labs_earnngs.jpg

    Abbott Laboratories Wednesday said second-quarter earnings jumped 34 percent, beating its expectations, fueled by sizzling sales of its medical devices, Humira arthritis treatment and other drugs.

  • Which is the Street more worried about--declining stock prices, particularly for financials, or inflation? It's both, and this morning's action illustrates that concern. It's been a roller coaster of a morning, up on Wells Fargo, down on consumer inflation higher than expected.

  • Oil's move could be a key trend in Wednesday's markets, as traders watch more Fed testimony, a bunch of earnings reports and another helping of inflation data.

  • To give investors an edge in this volatile market environment, CNBC asked the experts for their best trades now. 

  • At a time of market uncertainty, what can an investor count on?  Knee replacements, for one thing.  Bruce Nudell, UBS senior research analyst, takes that as his cue in picking some promising stocks.

  • The debate about whether stocks are finding a floor is gaining momentum, but traders agree it's the earnings season that will help decide the details.

  • graphic_word_ofthe_street.jpg

    The Dow rose Tuesday in another turbulent session after a pullback in oil prices eased worries about consumer and business spending. What's the "Word on the Street?"